

A.P. DO NOT ENTER 5/17/2009

BRAUNGER et al.
USSN 10/542,088
Page 2 of 9

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1.-88. (Canceled)

89. (Previously presented) A method for treating acute myeloid leukemia (AML) in a mammal, comprising administering to said mammal therapeutically effective amounts of (i) a compound selected from the group consisting of 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST], 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxy-pyrid-4-yl)-benzamide (Roflumilast-N-Oxide) and pharmaceutically acceptable salts thereof; and (ii) all trans retinoic acid.

90. (Previously presented) The method according to claim 89, wherein the compound is 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)-benzamide [INN: ROFLUMILAST] or a pharmaceutically acceptable salt thereof.

91. (Previously presented) The method according to claim 89, wherein the compound is 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxy-pyrid-4-yl)-benzamide (Roflumilast-N-Oxide) or a pharmaceutically acceptable salt thereof.